Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03403621
Other study ID # 17-005230
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date March 5, 2018
Est. completion date February 26, 2020

Study information

Verified date November 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are trying to find out more about the side effects of topical (applied to the skin) Pentamidine, to determine if it is safe for use in people. They also want to find out if topical use of Pentamidine can help treat hypertrophic scars. Pentamidine is a medicine that is currently used to treat certain kinds of infection. It is most often given by intravenous (into a vein) or inhalation (through a breathing device). This medication is approved by the U.S. Food and Drug Administration (FDA) for use in these forms. Everyone in this study will receive topical Pentamidine (TP) in a silicone based gel (PCCA Pracasil Plus). Topical treatment of Pentamidine is still experimental and has not been formally tested for safety or effectiveness in a randomized control trial within the United States. The FDA has allowed the use of topical Pentamidine in this research study.


Description:

This study will investigate Pentamidine isethionate, compounded in a silicone-containing base, as adjuvant therapy to surgical scar excision to prevent adverse scarring and enhance skin rejuvenation.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date February 26, 2020
Est. primary completion date February 26, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of hypertrophic scar by a Mayo Clinic plastic surgeon or dermatologist. - Target disease or condition: Hypertrophic scar - Subject with a hypertrophic scar that meet all of the following criteria: - Linear scar =5 to =40 cm in length - Present for minimum 6 months - Located anywhere in the body except on the face or front of neck - Resulting from surgical or traumatic injury, or other scar considered appropriate for surgical excision - Ability to safely undergo scar excision surgery - Capacity to provide informed consent - Ability to comply with protocol - Subject is judged, by the clinical investigator, to be healthy as evidenced by lack of clinically significant abnormal findings on medical history, physical examination, electrocardiogram, vital signs, and clinical laboratory tests. Exclusion Criteria: - Subjects identified as having a keloid or a scar not appropriate for surgical excision - Subjects who are positive for hepatitis B surface antigen (HbsAg), hepatitis C antibody and HIV as determined in screening the subject's electronic medical record. - Concurrent use of corticosteroids (including inhaled steroids), cyclooxygenase-2 (COX-2) inhibitors and/or drugs that are strong inhibitors and inducers of cytochrome P450 (CYP) enzymes - Are immuno-compromised (HIV infected, cancer and other disease affecting the basal immune response) - Clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurological, psychiatric, immunological, gastrointestinal, hematological, or metabolic disease that is, in the opinion of the investigator, not stabilized or may otherwise impact the results of the study. - Subjects with renal and hepatic impairment. - Known allergy or hypersensitivity to the study drug(s) or one of the ingredients of the formulation. - Any infection or wound in the area to treat including photosensitive dermatosis or inflammatory acne. - Existence of any surgical, medical or laboratory condition that, in the judgment of the clinical investigator, might interfere with the safety, distribution, metabolism or excretion of the drug - Participation in another clinical study in the past 30 days or concurrent participation in another clinical trial. - Patients with poorly controlled diabetes mellitus (HbA1C = 8%), peripheral neuropathy, or known concomitant vascular problems. - Pregnant or lactating female patients. - Prisoners. - Subjects who smoke cigarettes and/or use other tobacco products.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pentamidine Isethionate
Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.
Placebo
No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serious Adverse Events Number of participants to experience serious adverse events as defined as death [due to treatment] or life threatening adverse experience [due to treatment], hospitalization [due to treatment], persistent or significant disability or incapacity [due to treatment], birth defect/anomalies [due to treatment] and tissue necrosis [due to treatment]. 4 weeks post-operatively
Secondary Adverse Events Number of participants to experience adverse events as defined as skin infection, skin irritation and wound dehiscence. Skin irritation is scored by local skin reaction (LSR) grading scale. Wound infection is defined by skin that is red, swollen, hot and painful ("calor, dolor, rubor, tumor") [by clinical exam] with or without discharge. Wound dehiscence is defined as a measurable breaking open of the surgical incision along the suture. 4 weeks post-operatively
Secondary Change in Scar Volume Ultrasound will be used to quantify hypertrophic scar dimensions (length, width and height) and volume size using cm^3 as the unit of measure. Baseline (pre-operatively) and at postop week 2 and 4.
Secondary Change in Scar Fibrosis Semi-quantitative assessment of scar fibrosis on skin punch biopsy using a scale of none(1) - mild(2) - moderate(3) - severe(4) Baseline (preoperatively) and 4 weeks post-operatively.
Secondary Change in Scar Sclerosis Semi-quantitative assessment of scar sclerosis on skin punch biopsy using a scale of none(1) - mild(2) - moderate(3) - severe(4) Baseline (preoperatively) and 4 weeks post-operatively.
Secondary Change in Scar Angioplasia Semi-quantitative assessment of scar angioplasia on skin punch biopsy using a scale of none(1) - mild(2) - moderate(3) - severe(4) Baseline (preoperatively) and 4 weeks post-operatively.
Secondary Change in Scar Relative Depth Semi-quantitative assessment of scar relative depth on skin punch biopsy using a scale of Epidermis(1) - Mid-Reticular Dermis (2) - Deep Dermis(3) - Fat(4) Baseline (preoperatively) and 4 weeks post-operatively
Secondary Change in Scar Absolute Depth Measurement of scar absolute depth on skin punch biopsy reporting in millimeters (mm) Baseline (preoperatively) and 4 weeks post-operatively
Secondary Vancouver Scar Scale (VSS) The VSS assesses 4 variables: vascularity, height/thickness, pliability, and pigmentation. Scale ranges are as follows. Pigmentation (0=normal, 1=hypopigmentation, 2=hyperpigmentation). Height (0=flat, 1=less than 2 mm, 2=2 to 5 mm, 3=greater than 5 mm). Vascularity (0=normal, 1=pink, 2=red, 3=purple). Pliability (0=normal, 1=supple, 2=yielding, 3=firm, 4=banding,5=contracture). Total score can range from 0 to 13, with 0=normal skin, and 13=severe scarring. Baseline (preoperatively) and at weeks 2 and 4.
Secondary Patient Scar Assessment Scale (PSAS) The patient scar scale assesses pain, itching, color, stiffness, thickness, and irregularity. The scale rates each variable on a scale from 1 (normal skin) to 10 (worst scar imaginable), with a total possible score ranging from 1 (normal) to 120 (worst scar imaginable). Baseline (preoperatively) and at weeks 2 and 4.
Secondary Observer Scar Assessment Scale (OSAS) The observer scar assessment scale assesses vascularity, pigmentation, thickness, relief, pliability, and surface area. The scale rates each variable on a scale from 1 (normal skin) to 10 (worst scar imaginable), with a total possible score ranging from 1 (normal) to 120 (worst scar imaginable). Baseline (preoperatively), 2 weeks, and 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT03376620 - Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients Phase 3
Terminated NCT03935594 - Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars Phase 2
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Recruiting NCT06033430 - Effectiveness of Dry Needling in Linear Scar Tissue N/A
Recruiting NCT03631368 - Treatment of Hypertrophic Scars With Intradermal Botox Phase 2
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Recruiting NCT02168634 - The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial N/A
Completed NCT02030275 - A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults Phase 2
Recruiting NCT04506255 - Silicone Taping for the Improvement of Abdominal Donor Site Scars N/A
Not yet recruiting NCT04593706 - Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) N/A
Completed NCT04643223 - Effect of Elastic Bandage With Tension on the Inflammatory Response of Hypertrophic Scars N/A
Completed NCT03986346 - The Vascularity Changes of Scars With Laser Therapy N/A
Completed NCT04619589 - Characterization of Dyschromic Hypertrophic Scar
Completed NCT05412745 - Class I Medical Device on Post-surgical Scars N/A
Completed NCT06347081 - Effect of Nd-YAG Laser on Hypertrophic Scar N/A
Completed NCT00754247 - A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars Phase 4
Recruiting NCT03692273 - Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar N/A
Completed NCT03795116 - Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention Phase 2
Not yet recruiting NCT03850119 - Nanofat on Wound Healing and Scar Formation N/A
Recruiting NCT04364217 - Pain and Itch Reduction in Burn Scars Treated With Fractional CO2 Laser N/A

External Links